Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus chemotherapy for adult relapsed/refractory ALL
ChiCTR2100049664Phase 4Not yet recruiting
- Sponsor
- The Peoples' Hospital of Jiaozuo City
- Start
- Sep 2021
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bortezomib in acute lymphoblastic leukemia (ALL), sponsored by The Peoples' Hospital of Jiaozuo City. Primary endpoints: complete remission rate, minimal residual disease and 2 more. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2100049664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100049664.